Matches in SemOpenAlex for { <https://semopenalex.org/work/W3175700949> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W3175700949 endingPage "OR" @default.
- W3175700949 startingPage "320" @default.
- W3175700949 abstract "In the EMPA REG OUTCOME trial, empagliflozin (EMPA) reduced the risk of cardiovascular (CV) death, all-cause mortality, and hospitalization for heart failure (HHF) in patients with type 2 diabetes (T2D) and established CV disease (CVD). We assessed the CV effectiveness of EMPA in real-world T2D patients with and without CVD within EMPRISE, a study on the effectiveness, safety and healthcare utilization of EMPA, based on Medicare and 2 U.S. commercial claims datasets (2014-2019). Using data from 2014-2018 (2014-2017 in Medicare), we identified 1:1 propensity score-matched patients ≥18 years with T2D initiating EMPA or a DPP4 inhibitor (DPP4i) with and without CVD (14,920 and 40,443 matched pairs). We assessed HHF, a composite of MI or stroke, an expanded atherosclerotic CV (ASCV) event (MI, stroke, unstable angina, or coronary revascularization), and death. We estimated pooled HR and RD with 95% CI adjusting for >140 covariates. Over a mean follow-up of 6.3 months, EMPA vs. DPP4i initiators with and without CVD had reductions in the risk of HHF [HR, 0.71 (0.60-0.84) and 0.55 (0.42-0.73)] and mortality [HR, 0.53 (0.37-0.76) and 0.46 (0.29-0.74)], with larger benefits in patients with CVD on an absolute risk scale as shown by RD, but similar risk of ASCV events, including MI or stroke (Table). EMPA was associated with risk reductions in HHF and mortality, but similar risk of ASCV events in patients with and without CVD.View largeDownload slideView largeDownload slide DisclosureE. Patorno: Research Support; Self; Boehringer Ingelheim International GmbH, National Institutes of Health. S. Schneeweiss: Other Relationship; Self; Aetion. H. Tesfaye: None. D. J. Wexler: Board Member; Self; Novo Nordisk. R. Glynn: Research Support; Self; AstraZeneca, Kowa Research Institute, Inc., Novartis AG, Pfizer Inc. M. Najafzadeh: None. L. G. Bessette: Consultant; Self; Aetion, Inc. L. Zabotka: None. L. Koeneman: Employee; Self; Eli Lilly and Company, Stock/Shareholder; Self; Eli Lilly and Company. A. Deruaz-luyet: Employee; Self; Boehringer Ingelheim (Canada) Ltd., Employee; Spouse/Partner; Sanofi-Aventis Deutschland GmbH." @default.
- W3175700949 created "2021-07-05" @default.
- W3175700949 creator A5004416630 @default.
- W3175700949 creator A5030822229 @default.
- W3175700949 creator A5037108542 @default.
- W3175700949 creator A5037322697 @default.
- W3175700949 creator A5042008537 @default.
- W3175700949 creator A5044094148 @default.
- W3175700949 creator A5044474781 @default.
- W3175700949 creator A5045723863 @default.
- W3175700949 creator A5074777366 @default.
- W3175700949 creator A5076997901 @default.
- W3175700949 date "2021-06-01" @default.
- W3175700949 modified "2023-09-23" @default.
- W3175700949 title "320-OR: Cardiovascular Effectiveness of Empagliflozin in Patients with and without Cardiovascular Disease" @default.
- W3175700949 doi "https://doi.org/10.2337/db21-320-or" @default.
- W3175700949 hasPublicationYear "2021" @default.
- W3175700949 type Work @default.
- W3175700949 sameAs 3175700949 @default.
- W3175700949 citedByCount "0" @default.
- W3175700949 crossrefType "journal-article" @default.
- W3175700949 hasAuthorship W3175700949A5004416630 @default.
- W3175700949 hasAuthorship W3175700949A5030822229 @default.
- W3175700949 hasAuthorship W3175700949A5037108542 @default.
- W3175700949 hasAuthorship W3175700949A5037322697 @default.
- W3175700949 hasAuthorship W3175700949A5042008537 @default.
- W3175700949 hasAuthorship W3175700949A5044094148 @default.
- W3175700949 hasAuthorship W3175700949A5044474781 @default.
- W3175700949 hasAuthorship W3175700949A5045723863 @default.
- W3175700949 hasAuthorship W3175700949A5074777366 @default.
- W3175700949 hasAuthorship W3175700949A5076997901 @default.
- W3175700949 hasConcept C126322002 @default.
- W3175700949 hasConcept C127413603 @default.
- W3175700949 hasConcept C134018914 @default.
- W3175700949 hasConcept C138411078 @default.
- W3175700949 hasConcept C164705383 @default.
- W3175700949 hasConcept C185592680 @default.
- W3175700949 hasConcept C199289684 @default.
- W3175700949 hasConcept C2775887513 @default.
- W3175700949 hasConcept C2777180221 @default.
- W3175700949 hasConcept C2778425758 @default.
- W3175700949 hasConcept C2780645631 @default.
- W3175700949 hasConcept C2780652884 @default.
- W3175700949 hasConcept C500558357 @default.
- W3175700949 hasConcept C555293320 @default.
- W3175700949 hasConcept C71924100 @default.
- W3175700949 hasConcept C78519656 @default.
- W3175700949 hasConceptScore W3175700949C126322002 @default.
- W3175700949 hasConceptScore W3175700949C127413603 @default.
- W3175700949 hasConceptScore W3175700949C134018914 @default.
- W3175700949 hasConceptScore W3175700949C138411078 @default.
- W3175700949 hasConceptScore W3175700949C164705383 @default.
- W3175700949 hasConceptScore W3175700949C185592680 @default.
- W3175700949 hasConceptScore W3175700949C199289684 @default.
- W3175700949 hasConceptScore W3175700949C2775887513 @default.
- W3175700949 hasConceptScore W3175700949C2777180221 @default.
- W3175700949 hasConceptScore W3175700949C2778425758 @default.
- W3175700949 hasConceptScore W3175700949C2780645631 @default.
- W3175700949 hasConceptScore W3175700949C2780652884 @default.
- W3175700949 hasConceptScore W3175700949C500558357 @default.
- W3175700949 hasConceptScore W3175700949C555293320 @default.
- W3175700949 hasConceptScore W3175700949C71924100 @default.
- W3175700949 hasConceptScore W3175700949C78519656 @default.
- W3175700949 hasIssue "Supplement 1" @default.
- W3175700949 hasLocation W31757009491 @default.
- W3175700949 hasOpenAccess W3175700949 @default.
- W3175700949 hasPrimaryLocation W31757009491 @default.
- W3175700949 hasRelatedWork W2049397185 @default.
- W3175700949 hasRelatedWork W2383009242 @default.
- W3175700949 hasRelatedWork W2399063111 @default.
- W3175700949 hasRelatedWork W2588682962 @default.
- W3175700949 hasRelatedWork W2610912351 @default.
- W3175700949 hasRelatedWork W2744452336 @default.
- W3175700949 hasRelatedWork W2893676915 @default.
- W3175700949 hasRelatedWork W2981371482 @default.
- W3175700949 hasRelatedWork W3166176528 @default.
- W3175700949 hasRelatedWork W4251115415 @default.
- W3175700949 hasVolume "70" @default.
- W3175700949 isParatext "false" @default.
- W3175700949 isRetracted "false" @default.
- W3175700949 magId "3175700949" @default.
- W3175700949 workType "article" @default.